VOOPOO
7.1.2022 13:02:14 CET | Business Wire | Press release
At the start of the new year 2022, VOOPOO , always in pursuit of unique industrial designs, has made another big move. On January 5, it launched Vinci Pod Royal Edition with a new relief design. Its shining and lightweight overall shape emphasizes a retro feel while also showing a strong aristocratic atmosphere.
Original relief craftsmanship for Pod
A large number of relief artworks have been unearthed from the ancient Sumerian Ruins, one of the birthplaces of human civilization. In contemporary times, there are also plenty of art products using relief craftsmanship. According to Vivian, Head of VOOPOO Product Development Team, “It is precisely the ancient relief artworks and the fashionable and retro contemporary elements that inspired us to develop the Vinci Pod Royal Edition series. Our original purpose is to explore the artistic and cultural value of the Pod product itself, so that users can also show their artistic taste in the process of using the product.”
However, it is no easy to engrave relief patterns on delicate Pod products. Any slight fault in the process will result in failure to achieve art-grade quality. The six products of the VOOPOO Vinci Pod Royal Edition series are all designed by experienced artists and are also integrated with design elements from retro jazz and cool graffiti styles. Product development took 8 months, and 12 manufacture processes and 68 techniques were involved, with 80% of the work completed by hand. The products were a result of the collaboration of more than 20 people including industrial designers, structural designers, and R&D members.
In addition to the unique relief itself, the tactile experience brought by the relief is even more impressive. Since the relief pattern of each product is different, customers can choose according to their own visual and tactile preferences. When the Pod of "tactile beauty" is held in your hand, you can experience an artistic masterpiece with its concave-convex surface, allowing you to enjoy a noble experience at your fingertip.
Focused on the user's product experience
In addition to the appearance, the product’s material and user experience also fit the users’ habits. The VOOPOO product development team has chosen the 6061 aviation-grade aluminum alloy, which boasts excellent strength, plasticity, fracture toughness, fatigue resistance, stress corrosion cracking resistance and exfoliation corrosion resistance, and has been widely used in aerospace, high-speed rail and automotive industries. It is worth noting that after 268 precise airflow experiments, the transmitter and airway design of VINCI Pod Royal Edition has been well optimized, bringing unparalleled comfort to the mouth-sucking experience.
VINCI Pod Royal Edition comes with the visual VINCI POD cartridge, which allows users to see the remaining e-liquid in real time, so that they can refill in time and refrain from anxiety. At the same time, VINCI Pod Royal Edition is equipped with 0.8Ω and 1.2Ω atomizers for users to enjoy different levels of taste and nicotine experience according to their preferences. VINCI Pod Royal Edition has also perfectly integrated the breathing light, so that it lights up when the user is inhaling, and goes off when stopping, providing users the strong dynamic sense.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
Voopoo website: https://www.voopoo.com/
IG: https://www.instagram.com/voopoo_global/
https://www.instagram.com/voopootechofficial/
Facebook: https://www.facebook.com/Voopootech/
Tiktok: https://www.tiktok.com/@voopoo_indonesia?lang=en
Please view the original press release at businesswire.com: https://www.businesswire.com/news/home/20220105006068/zh-CN/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105006058/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom